Mindray Launches Two New Cardiac Biomarker Tests for Myocardial Infarction and Heart Failure
Mindray has announced the launch of two high-sensitivity cardiac biomarkers, hs-cTnI and NT-proBNP, as part of its extensive portfolio of cardiac biomarkers aimed at diagnosing and managing cardiovascular diseases. Clinical guidelines recommend the use of cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) as essential biomarkers for diagnosing Acute Coronary Syndrome (ACS) and heart failure. Mindray’s hs-cTnI and NT-proBNP assays are the result of a successful collaboration between Mindray and HyTest, a globally recognized provider of antibodies and antigens that was acquired by Mindray in 2021. HyTest, renowned for its expertise in cardiac biomarkers, had its cardiac troponin complex material selected as the international troponin standard by the American Association for Clinical Chemistry (AACC) in 2004.
The new high-sensitivity cardiac troponin I assay exceeds the minimum requirements for hs-cTn by offering high accuracy and low variability in detecting myocardial injury. The test offers rapid turnaround in the critical 0-2 window. Cardiac troponin is commonly tested for in emergency rooms for triage of patients presenting with signs of myocardial infarction (heart attack).
The NT-proBNP is a well-established cardiac marker for heart failure and its management. Mindray’s NT-proBNP assay offers high precision with a CV of ≤5% and effectively minimizes interference from 55 common medications used for heart diseases.
Dr. Jianwen He, Chief Scientific Officer of Mindray IVD, emphasized the collaborative effort that has led to the development of these advanced biomarkers. By integrating HyTest’s pioneering antibodies and research on cardiac biomarkers with Mindray’s cutting-edge reagent technology and platform, they aim to deliver more reliable solutions that significantly enhance patient outcomes in the realm of cardiovascular diseases.